Search results for "Administration"

showing 10 items of 5106 documents

Gonadotropin and Testosterone Secretion in Normal Human Males After Stimulation With Gonadotropin-Releasing Hormone (Gnrh) or Potent Gnrh Analogs Usi…

1978

Gonadotropin-releasing hormone (GnRH) and some potent long-acting GnRH analogs, applied by different routes of administration, were tested in six healthy human males. The effects on gonadotropin secretion were compared with the one after intravenous (i.v.) bolus injection of 25 microgram of GnRH. The net increase of luteinizing hormone (deltaLH) in serum produced by 25 microgram of GnRH i.v. was matched by subcutaneous (s.c.) injection of 100 microgram of GnRH, dissolved in 20% gelatin or without gelatin; 5 microgram of D-Ser (TBU)6-des-Gly10-GnRH-ethylamide i.v.; 5 microgram of D-Leu6-des-Gly10-GnRH-ethylamide i.v.; and 50 microgram of D-Trp6-des Gly10-GnRH-ethylamide given pernasally (p.n…

AdultMaleendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classMicrogramStimulationGonadotropin-releasing hormoneGonadotropin-Releasing HormoneInternal medicinemedicineHumansInfusions ParenteralTestosteroneAdministration IntranasalChemistryObstetrics and GynecologyLuteinizing HormoneHormonesGonadotropin secretionEndocrinologyReproductive MedicineInjections IntravenousNasal administrationFollicle Stimulating HormoneGonadotropinLuteinizing hormonePituitary Hormone-Releasing Hormoneshormones hormone substitutes and hormone antagonistsHormoneFertility and Sterility
researchProduct

Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.

2014

Abstract The aim of this randomized, crossover, comparison study was to assess the analgesic and adverse effects of 2 nasal preparations, intranasal fentanyl (INFS) and fentanyl pectin nasal spray (FPNS), for breakthrough pain, given in doses proportional to opioid basal regimen. Each patient randomly received INFS or FPNS in doses proportional to opioid dosages used for background analgesia for 2 pairs of episodes. For each episode of breakthrough pain, pain intensity and adverse effects intensity were recorded just before starting the INFS or FPNS (T0) and 5 minutes (T5), 10 minutes (T10), and 20 minutes (T20) after the administration of the nasal drugs. Sixty-nine patients were studied. …

AdultMalefentanyl pectin nasal spraymedicine.medical_treatmentAnalgesicSettore MED/42 - Igiene Generale E ApplicataFentanylrapid-onset opioidsNeoplasmsparasitic diseasesMedicineHumansCancer painAdverse effectAgedPain MeasurementAged 80 and overDose-Response Relationship Drugbusiness.industryBreakthrough Painintranasal fentanylNasal SpraysMiddle AgedCancer pain; breakthrough pain; fentanyl pectin nasal spray; intranasal fentanyl; rapid-onset opioidsAnalgesics OpioidFentanylRegimenAnesthesiology and Pain MedicineCross-Sectional StudiesNeurologyOpioidNasal sprayAnesthesiaPectinsNasal administrationFemaleNeurology (clinical)businessCancer painmedicine.drugThe journal of pain
researchProduct

Antibacterial susceptibility patterns of Porphyromonas gingivalis isolated from chronic Periodontitis patients

2010

Objectives: To test the antimicrobial sensitivity of Porphyromonas gingivalis to a panel of eight orally administrable antibiotics in chronic periodontal diseases and to evaluate factors associated with periodontitis in adult patients. Study Design: A total of fifty strains of P. gingivalis were isolated from one hundred and twenty adult patients with chronic perio-dontitis. Identification of bacteria was carried out by anaerobic culture and biochemical tests. Selected colonies of P. gingivalis were used to evaluate the antibacterial activities of penicillin, metronidazole, amoxicillin, amoxicillin/clavulanic acid, clindamycin, doxy-cycline, ciprofloxacin and azithromycin. Results: Most of …

AdultMalemedicine.drug_classAntibioticsAdministration OralMicrobial Sensitivity TestsAzithromycinMicrobiologyClavulanic acidmedicineHumansPeriodontitisGeneral DentistryPorphyromonas gingivalisPeriodontitisbiologybusiness.industryMiddle AgedAmoxicillin:CIENCIAS MÉDICAS [UNESCO]medicine.diseasebiology.organism_classificationChronic periodontitisAnti-Bacterial AgentsCiprofloxacinOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASChronic DiseaseFemaleSurgerybusinessPorphyromonas gingivalismedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Influence of low temperature on bronchodilatation induced by terbutaline administered by metered dose or dry powder inhalers in asthmatics.

2000

Low temperatures may affect dose delivery efficacy and clinical effectiveness of medication aerosols. In this study we examine the effect of cold ambient temperature on the bronchodilatation produced by terbutaline delivered from a chlorofluorocarbon pressurized metered dose inhaler (pMDI) compared to a multi-dose dry powder inhaler (DPI). Fourteen stable asthmatics were studied on two consecutive days. On day 1, after measuring FEV1 at room temperature (22 degrees C), each patient was randomized to receive 500 microg of terbutaline delivered from pMDI or DPI stored for 24 h at 22 degrees C with FEV1 recorded 20 min post-dose; then, patients were placed in a chamber at -10 degrees C, and af…

AdultMalemedicine.drug_classTerbutalineCold storageBronchiBronchodilatorForced Expiratory VolumeAdministration InhalationmedicineTerbutalineHumansPharmacology (medical)PharmacologyDose-Response Relationship DrugCumulative doseChemistryInhalerAdrenergic beta-AgonistsMiddle AgedMetered-dose inhalerDry-powder inhalerAsthmaBronchodilator AgentsCold TemperatureBronchodilatationAnesthesiaFemalePowdersmedicine.drugFundamentalclinical pharmacology
researchProduct

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a …

2007

Abstract Background To compare the efficacy and safety of three different chemotherapy doublets in the treatment of advanced pancreatic cancer (PC). Patients and methods At total of 190 patients were randomly assigned to receive capecitabine 1000 mg/m2 twice daily on days 1–14 plus oxaliplatin 130 mg/m2 on day 1 (CapOx), capecitabine 825 mg/m2 twice daily on days 1–14 plus gemcitabine 1000 mg/m2 on days 1 and 8 (CapGem) or gemcitabine 1000 mg/m2 on days 1 and 8 plus oxaliplatin 130 mg/m2 on day 8 (mGemOx). Treatment cycles were repeated every three weeks. The primary end point was progression-free survival (PFS) rate at 3 months; secondary end points included objective response rate, carboh…

AdultMalemedicine.medical_specialtyAdolescentMaximum Tolerated DoseOrganoplatinum CompoundsPhases of clinical researchKaplan-Meier EstimateDeoxycytidineRisk AssessmentGastroenterologyDisease-Free SurvivalDrug Administration ScheduleCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSingle-Blind MethodProgression-free survivalInfusions IntravenousCapecitabineAgedNeoplasm StagingProbabilityDose-Response Relationship Drugbusiness.industryCAPOX RegimenHematologyMiddle AgedImmunohistochemistrySurvival AnalysisGemcitabineGemcitabineOxaliplatinSurgeryOxaliplatinPancreatic NeoplasmsRegimenTreatment OutcomeOncologyTolerabilityFemaleFluorouracilbusinessFollow-Up Studiesmedicine.drugAnnals of Oncology
researchProduct

Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depressi…

2003

OBJECTIVE Current clinical knowledge holds that antidepressants have a delayed onset of efficacy. However, the delayed onset hypothesis has been questioned recently by survival analytical approaches. We aimed to test whether early improvement under antidepressant treatment is a clinically useful predictor of later stable response and remission. METHOD We analyzed data from a randomized double-blind controlled trial with mirtazapine and paroxetine in patients with major depression (DSM-IV). Improvement was defined as a 17-item Hamilton Rating Scale for Depression (HAM-D-17) score reduction of > or = 20%. Stable response was defined as > or = 50% HAM-D-17 score reduction at week 4 and week 6,…

AdultMalemedicine.medical_specialtyAdolescentMirtazapineMirtazapineMianserinAntidepressive Agents TricyclicDrug Administration Schedulelaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineAmbulatory CareHumansPsychiatrySurvival analysisDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressive DisorderHamilton Rating Scale for DepressionMiddle AgedPrognosisParoxetineSurvival AnalysisClinical trialPsychiatry and Mental healthParoxetineTreatment OutcomeAntidepressantDrug Therapy CombinationFemalePsychologySelective Serotonin Reuptake Inhibitorsmedicine.drug
researchProduct

Handling forces for the use of different inhaler devices.

2019

Abstract Age and comorbidities can impact on the success of handling an inhaler. In this pilot study, we assessed finger strength in 62 participants (aged 5–17 years [n = 20], 18–65 years [n = 22] and > 65 years [n = 20]) by using different types of inhalers with integrated sensors (Respimat®, Breezhaler®, Aerolizer®, Genuair®, Diskus®, Ellipta®, HandiHaler®, Turbohaler® and a pressurized metered-dose inhaler [Atrovent®]). Parameters under investigation included the spontaneous and maximum achievable force and torque required to operate devices. Satisfaction with individual inhalers, and the relationship between satisfaction and strength, were also assessed. There was a marked difference in…

AdultMalemedicine.medical_specialtyAdolescentPharmaceutical SciencePilot Projects02 engineering and technology030226 pharmacology & pharmacyFingers03 medical and health sciencesYoung Adult0302 clinical medicineAge groupsRheumatic DiseasesAdministration InhalationMedicineHumansChildAgedAged 80 and overHand Strengthbusiness.industryInhalerNebulizers and VaporizersHealthy subjectsAge FactorsRheumatic diseaseEquipment DesignMiddle Aged021001 nanoscience & nanotechnologyPatient preferenceDry-powder inhalerPatient SatisfactionCase-Control StudiesChild PreschoolPhysical therapyFemale0210 nano-technologybusinessInternational journal of pharmaceutics
researchProduct

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

2012

BACKGROUND: Some patients with severe asthma have recurrent asthma exacerbations associated with eosinophilic airway inflammation. Early studies suggest that inhibition of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exacerbations. We aimed to establish efficacy, safety, and patient characteristics associated with the response to mepolizumab. METHODS: We undertook a multicentre, double-blind, placebo-controlled trial at 81 centres in 13 countries between Nov 9, 2009, and Dec 5, 2011. Eligible patients were aged 12-74 years, had a history of recurrent severe asthma exacerbations, and had signs of eosinophil…

AdultMalemedicine.medical_specialtyAdolescentPlacebo-controlled studyFevipiprantAntibodies Monoclonal HumanizedPlaceboLebrikizumabDrug Administration ScheduleLeukocyte CountYoung Adultchemistry.chemical_compoundDouble-Blind MethodReslizumabInternal medicineSecondary PreventionmedicineHumansAnti-Asthmatic AgentsPulmonary EosinophiliaChildGlucocorticoidsAgedAsthmaDose-Response Relationship Drugbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseBenralizumabAsthmaEosinophilsTreatment OutcomechemistryPhysical therapyDrug Therapy CombinationFemaleInterleukin-5businessMepolizumabmedicine.drugThe Lancet
researchProduct

Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large mu…

2011

In β-thalassemia major (β-TM) patients, iron chelation therapy is mandatory to reduce iron overload secondary to transfusions. Recommended first line treatment is deferoxamine (DFO) from the age of 2 and second line treatment after the age of 6 is deferiprone (L1). A multicenter randomized open-label trial was designed to assess the effectiveness of long-term alternating sequential L1-DFO versus L1 alone iron chelation therapy in β-TM patients. Deferiprone 75 mg/kg 4 days/week and DFO 50 mg/kg/day for 3 days/week was compared with L1 alone 75 mg/kg 7 days/week during 5-year follow-up. A total of 213 thalassemia patients were randomized and underwent intention-to-treat analysis. Statisticall…

AdultMalemedicine.medical_specialtyAdolescentPyridonesThalassemiaClinical BiochemistryDeferoxamineIron Chelating AgentsGastroenterologyDrug Administration Schedulelaw.inventionchemistry.chemical_compoundYoung AdultRandomized controlled triallawInternal medicineMedicineHumansDeferiproneAdverse effectGenetics (clinical)Survival analysisbusiness.industryBiochemistry (medical)Serum ferritin levelbeta-ThalassemiaHematologyIron chelation therapymedicine.diseaseChelation TherapyDeferoxamineTreatment OutcomechemistryDrug Therapy CombinationFemalebusinessDeferiproneThalassemia Iron overload Iron chelation therapy Deferiprone (L1) Deferroxamine (DFO)medicine.drugFollow-Up StudiesHemoglobin
researchProduct

Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy

2014

Abstract Background Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. Methods One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall co…

AdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIAmedicine.medical_treatmentUlcerative colitis;GastroenterologyDrug Administration ScheduleYoung AdultAdrenal Cortex HormonesInternal medicineHumansMedicineTreatment FailureAdverse effectColectomyInfliximab;AgedColectomyIntention-to-treat analysisbusiness.industryAnti-Inflammatory Agents Non-SteroidalGastroenterologyAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseUlcerative colitisInfliximabInfliximabRegimenTreatment OutcomeUlcerative colitisRelative riskCohortColitis UlcerativeFemalebusinessmedicine.drugJournal of Crohn's and Colitis
researchProduct